Table 3.
Univariate analysis of conditions associated with cumulative incidence of SARS-CoV-2 infection in allo-HSCT and ASCT recipients.
| Characteristics | Allo-SCT Cum. Inc (C.I. (95%) | P Value | ASCT Cum Inc (C.I. 95%) | P value |
|---|---|---|---|---|
| COVID-19 pre-vaccination | 0.01 | 0.6 | ||
| • Yes | 0 | 24 (0–53) | ||
| • No | 14.4 (11–18) | 20.2 (12–28) | ||
| Type of 1st and 2nd vaccines, n (%) | 0.09 | 0.4 | ||
| ➣ Moderna mRNA-1273 | 13 (10–17) | 18 (14–26) | ||
| ➣ Pfizer-BioNTech BNT162b2 | 9 (2–16) | 28 (0–62) | ||
| ➣ Adenoviral vector-based | 33 (3–64) | 12 (0–53) | ||
| Age (years), median (range) | 0.2 | 0.3 | ||
| • 16–40 years | 18 (9–26) | 34 (0–75) | ||
| • 41–60 years | 14 (9–19) | 24 (11–36) | ||
| • 61–70 years | 10 (4–16) | 13 (3–23) | ||
| • >71 years | 4 (0–11) | 31 (6–56) | ||
| Sex | 0.4 | 0.5 | ||
| • Male | 15 (10–19) | 22 (11–32) | ||
| • Female | 11.3 (7–16) | 19 (8–30) | ||
| Baseline disease | 0.5 | 0.2 | ||
| • AML | 15 (9–21) | |||
| • ALL | 10 (2–19) | |||
| • MDS | 14 (5–22) | |||
| • B cell NHL | 10 (0.7–19 | 9 (0-20) | ||
| • T cell NHL | 12 (0–25) | |||
| • Plasma cell disorders | 12 (5–20) | 22 (12–32) | ||
| • CLL | 11 (0–26) | 35 (9–62) | ||
| • HD | 15 (2.1–27) | |||
| • cMPN | 15 (4–27) | |||
| • Aplastic anemia | 14 (4–25) | |||
| Time from transplant to vaccination | 0.8 | 0.8 | ||
| • <6 months | 13 (4–22) | 23 (0.2–46) | ||
| • 6 months to 1 year | 15 (5–25) | 8 (0–22) | ||
| • 1 year | 12.6 (9–16.4) | 22 (13–31) | ||
| Type of donor | 0.4 | |||
| • HLA identical sibling donor | 13 (8–18) | |||
| • URD | 16 (9–23) | |||
| • Haplo-identical family donor | 8 (3–14) | |||
| • UCBT | 17 (0–46) | |||
| Donor/recipient HLA mismatch | 0.3 | |||
| • Yes | 11 (5–16) | |||
| • No | 14.2 (10–18) | |||
| GvHD prophylaxis | 0.08 | |||
| • Post-Cy based | 11 (6–15) | |||
| • Not post-Cy | 15.9 (11–21) | |||
| ATG-based conditioning regimen | 0.5 | |||
| • ATG | 17 (2–32) | |||
| • No ATG | 12.9 (10–16.5) | |||
| Conditioning regimen intensity | 0.01 | |||
| • MAC | 18.1 (12–24) | |||
| • RIC | 10 (6–14) | |||
| IS drugs at vaccination | 0.002 | 0.7 | ||
| • Yes, with corticosteroids | 30 (14-47) | 24 (3–45) | ||
| • Yes, but w/o corticosteroids | 16.9 (10-24) | 22 (8–36) | ||
| • No | 10 (6–13) | 19 (9–29) | ||
| Corticosteroids at vaccination | 0.003 | 0.3 | ||
| • Yes | 30 (14–47) | 22 (8–36) | ||
| • No | 11.6 (8–14) | 20 (11–29) | ||
| Active GvHD at vaccination | 0.047 | |||
| • Yes | 17.6 (11–24) | |||
| • No | 11 (8–15) | |||
| Ruxolitinib | 0.5 | |||
| • Yes | 17 (2–32) | |||
| • No | 13 (9–16) | |||
| Lymphocyte count < 1 × 109/mL | 0.2 | 0.29 | ||
| • Yes | 18 (9–27) | 10 (0–24) | ||
| • No | 13 (9–16) | 22 (13–31) | ||
| Lymphocyte count < 0.5 × 109/mL | 0.2 | |||
| • Yes | 17 (0–35) | |||
| • No | 14 (10–17) |
OR odds ratio, Allo-HSCT allogeneic stem cell transplantation, URD adult unrelated donor, UCBT umbilical cord blood transplantation, HLA human leucocyte antigen, post-Cy post-transplant cyclophosphamide, CNI calcineurin inhibitor, ATG anti-thymocyte globulin, MAC myeloablative conditioning, RIC reduced intensity conditioning, IS Immunosuppressors, GvHD graft versus host disease, NT not tested.